Institut für Pharmakologie und Präventive Medizin
Quick facts
Marketed products
- Empagliflozin and Linagliptin
- Olmesartan/amlodipine · Cardiovascular
Olmesartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.
Phase 3 pipeline
- Metformin and Insulin sc · Diabetes
Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity, while insulin sc works by replacing or supplementing the body's natural insulin. - Olmesartan/Amlodipin · Cardiovascular
Olmesartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Institut für Pharmakologie und Präventive Medizin portfolio CI brief
- Institut für Pharmakologie und Präventive Medizin pipeline updates RSS
Frequently asked questions about Institut für Pharmakologie und Präventive Medizin
What are Institut für Pharmakologie und Präventive Medizin's marketed drugs?
Top marketed products include Empagliflozin and Linagliptin, Olmesartan/amlodipine.
What is Institut für Pharmakologie und Präventive Medizin's pipeline?
Institut für Pharmakologie und Präventive Medizin has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Metformin and Insulin sc, Olmesartan/Amlodipin.
Related
- Empagliflozin and Linagliptin
- Olmesartan/amlodipine · Cardiovascular
- Sector hub: All tracked pharma companies